UNSPSC 51111850: Gonadorelin

This classification denotes a gnrh1 gene with the molecular formula C55H75N17O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9O7312W37G, chemically known as gonadotropin, luteinizing hormone-releasing hormone, synthetic but generally known as gonadorelin, which bears US NIH Compound Identifier 36523. European Medicines Agency schedules Gonadorelin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07960MIG. The term GONADORELIN is an International Non-Proprietary Name.

UNSPSC 51111850 Gonadorelin, a Commodity code, covers pharmaceutical supply agreements for multi-source generic medications and over-the-counter products distributed through state and local government facilities. State and local buyers under this code procure pharmaceutical products through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions, with pricing, product availability, compliance certifications, and wholesaler-distribution capabilities as the primary evaluation drivers. Issuing bodies include state procurement offices administering multi-state cooperative purchasing alliances and the state and local government facilities that consume the products through those alliances.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon. Vendors must supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — and demonstrate cGMP and Drug Supply Chain Security Act (DSCSA) compliance, maintain contractual relationships with at least two of the three wholesalers with chargeback systems in place, and offer pricing in formats including flat price, net price (NF30, NF60, NF90), or WAC-minus structures. Evaluation weightings favor price competitiveness (75 percent), with smaller components for fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Products must be available in the marketplace by May 15, 2026, with contract terms of two years for new responders and optional extensions at MMCAP's discretion.